Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank
23 nov. 2020 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Announces November 2020 Virtual Investor Conference Participation
09 nov. 2020 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
29 oct. 2020 03h00 HE
|
Verona Pharma plc
Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot clinical study in U.S. patients hospitalized with COVID-19 ...
Verona Pharma plc : Update on AIM Delisting
28 oct. 2020 07h01 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intended...
Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update
22 oct. 2020 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...
Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020
13 oct. 2020 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...
Verona Pharma Initiates Phase 3 Clinical Trials with Nebulized Ensifentrine for the Maintenance Treatment of COPD
23 sept. 2020 04h06 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory...
Intended Delisting and Cancellation of Ordinary Shares from Trading on AIM
21 sept. 2020 02h00 HE
|
Verona Pharma plc
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW...
Verona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing
17 sept. 2020 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Announces Publication of Phase 2b COPD Symptom Data in the International Journal of Chronic Obstructive Pulmonary Disease
16 sept. 2020 08h25 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory...